Compare RKDA & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKDA | JAGX |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.2M |
| IPO Year | 2015 | 2014 |
| Metric | RKDA | JAGX |
|---|---|---|
| Price | $1.07 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 1.9M | 71.5K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.92 | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $4,858,000.00 | ★ $11,511,000.00 |
| Revenue This Year | $61.67 | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.22 |
| 52 Week High | $6.71 | $8.00 |
| Indicator | RKDA | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 47.96 |
| Support Level | $0.85 | $1.74 |
| Resistance Level | $1.51 | $4.13 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 27.62 | 2.11 |
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.